Angiotensin II human ≥93% (HPLC), powder

Properties

Related Categories	Angiotensins, Application Index, Biochemicals and Reagents, Cell Biology, Cell Signaling Enzymes, Cell Signaling and Neuroscience, Chymase and Related Products, Enzymes, Inhibitors, and Substrates, Neuropeptides, Peptides and Proteins, Peptides for Cell Biology More...
assay	≥93% (HPLC)
form	powder
impurities	1.2-10.4% acetate
storage temp.	−20°C
Gene Information	human ... AGT(183)

Description

Amino Acid Sequence

Asp-Arg-Val-Tyr-Ile-His-Pro-Phe

Antibody Adsorbant

Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH · 2CH₃COOH · H₂O

Analysis Note

Peptide content not less than 75%

Biochem/physiol Actions

Angiotensin (Ang) II is important in regulating cardiovascular hemodynamics and cardiovascular structure. Most of the known effects of Ang II in adult tissues are attributable to the angiotensin II type I (AT₁) receptor. The AT₁ and AT₂ receptors have differential pharmacological and biochemical properties and appear to exert opposite effects in terms of cardiovascular hemodynamics and cell growth. In addition, the renin-angiotensin and nitric oxide-generating systems appear to interract in the regulation of cardiovascular function. Ang II stimulates angiogenesis and increases microvessel density. In nature, angiotensin II is produced by the action of angiotensin converting enzyme on angiotensinogen; the C-terminal-His-Leu is cleaved.

Price and Availability

Related Papers

The renin-angiotensin system: an overview of its intracellular function. Inagami, T, et al. Cardiovasc. Drugs Ther. 2, 453-458, (1988)

Documents

Certificate of Analysis

Certificate of Origin

A9525 - Datasheet (79KB)

Angiotensin Receptors (178 KB )

Angiotensin Receptors (81 KB )

Celltransmissions 19(1) (143 KB )

Neuropeptidases (252 KB)

Neuropeptidases Classification (197 KB )

Safety Information

Personal Protective Equipment	Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
WGK Germany	3
RTECS	BW2165000

Technical information & documentation associated with this product is available in the Safety & Documentation tab.

Articles

Antihypertensive Agents

Download BioFiles v7 n5 (3.18 Mb PDF) Back to Pharmaceutical Drugs and Drug Candidates homepage
Sami Barghshoon
BioFiles v7 n5, 2012, 5–20
Keywords: AGE, Antihypertensives, Cardiovascular, Clinical, Diuretics, Pharmaceutical, Reductions

Lipid Induced Insulin Resistance

Obesity is a well-established risk factor for the development of insulin resistance. Obesity is associated with the increased deposition of lipids in non-adipose tissue with subsequent decreases in i...
Linda Stephenson, Ph.D.
Biofiles v6 n4, 9
Keywords: Angiogenesis, Antivirals, Apoptosis, Biological processes, Cardiovascular, Catalysis, Cell culture, Cell proliferation, Deposition, Diabetes, Gene expression, Growth factors, Hormones, Inflammation, Metabolism, Metabolites, Obesity, Phosphorylations, Physiological Processes, Reductions, Transcription, Transduction

Plasma Derived Proteins and Enzymes

Despite their complexity, blood and plasma are abundant biological resources for the discovery of drug targets and biomarkers for human disease. It is estimated that plasma may contain as many as 40,...
BioFiles 2006, 1.5, 2.
Keywords: Gas chromatography

Papers

Set your institution to view full text papers.

The renin-angiotensin system: an overview of its intracellular function. Inagami, T, et al. Cardiovasc. Drugs Ther. 2, 453-458, (1988)

Loading...

Nitric oxide and the renin-angiotensin system. Is there a physiological interplay between the systems? Fernandez-Alfonso, M.S., and Gonzalez, C. J. Hypertens. 17, 1355-61, (1999)

Loading...

Cross talk between angiotensin II type 1 and type 2 receptors: cellular mechanism of angiotensin type 2 receptor-mediated cell growth inhibition. Xoriuchi, M., et al. Hypertens. Res. 22, 67-74, (1999)

Loading...

Angiotensin receptors: molecular biology and signaling. Inagami, T. et al. Clin. Exp. Pharmacol. Physiol. 26, 544-549, (1999)

Loading...

Angiotnesin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. Yongzhong, W., et al. J. Biol. Chem. 281, 35137-35146, (2006)

Loading...

Angiotensin II induces premature senescence of vascular smooth muscle cells and accelerates the development of atherosclerosis via a p21-dependent pathway. Takeshige, K., et al. Circulation 114, 953-960, (2006)

Loading...

Beta-arrestins 1 and 2 differentially regulate LPS-induced signaling and pro-inflammatory gene expression. Fan, H., et al. Mol. Immunol. 44, 3092-9, (2007)

Loading...

Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation. Yang, X., et al. J. Histochem. Cytochem. 26, 1629-35, (2008)

Loading...

Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension. Sendra, J., et al. Carcinogenesis 78, 581-9, (2008)

Loading...

Protein kinase CK2 links extracellular growth factor signaling with the control of p27(Kip1) stability in the heart. Hauck, L., et al. Nat. Med. 14, 315-24, (2008)

Loading...

β-Arrestin-mediated Signaling Regulates Protein Synthesis DeWire, S.M., et al. J. Biol. Chem. 283, 10611 - 10620, (2008)

Loading...

Mechanisms of angiotensin II signaling on cytoskeleton of podocytes. Hsu, H.H., et al. J. Mol. Endocrinol. 86, 1379-94, (2008)

Loading...

Mouse hepatic portal venoconstrictive response to vasoconstrictors is much weaker than that in rat. Zhao, Z.S., et al. J. Cardiovasc. Pharmacol. 54, 421-6, (2009)

Loading...

Activation of MMP8 and MMP13 by angiotensin II correlates to severe intra-plaque hemorrhages and collagen breakdown in atherosclerotic lesions with a vulnerable phenotype. Cheng, C., et al. Atherosclerosis 204, 26-33, (2009)

Loading...

Absence of p55 TNF receptor reduces atherosclerosis, but has no major effect on angiotensin II induced aneurysms in LDL receptor deficient mice. Xanthoulea, S., et al. PLoS Biol. 4, e6113, (2009)

Loading...

Systemic Candesartan Reduces Brain Angiotensin II Via Downregulation Of Brain Renin-angiotensin System. Pelisch, N., et al. Hypertens. Res. 33, 161-4, (2010)

Loading...

Pharmacodynamic And Pharmacokinetic Characterization Of The Aldosterone Synthase Inhibitor FAD286 In Two Rodent Models Of Hyperaldosteronism: Comparison With The 11beta-hydroxylase Inhibitor Metyrapone. Rigel, D.F., et al. J. Nutr. 334, 232-43, (2010)

Estradiol decreases the orexigenic effect of neuropeptide Y, but not agouti-related protein, in ovariectomized rats. Jessica Santollo et al Behav. Brain Res. 191, 173-7, (2008)

Loading...

Modulation of human embryonic stem cell-derived cardiomyocyte growth: a testbed for studying human cardiac hypertrophy? Gábor Földes et al J. Mol. Cell. Cardiol. 50, 367-76, (2011)

Loading...